Literature DB >> 16025245

Inducible vesicular stomatitis virus (VSV) L cell line for packaging of recombinant VSV.

Seong-Karp Hong1, Yong-Tae Jung, Seung-Won Park, Soon-Young Paik.   

Abstract

Recently, recombinant vesicular stomatitis viruses (VSV) have been developed as high-level expression vectors which serve as effective vaccine vectors in animals. An ideal approach for VSV vector production would be the development of stable packaging cell lines that can produce vector particles without transfection step. In this report, we describe generation of an inducible cell line that expresses the VSV polymerase gene (L) under the control of the reverse tetracycline-controlled transactivator (rtTA) system as a first step to make VSV-based packaging cell lines. Integrated polymerase (L) gene was controlled by an rtetR-dependent promoter in the rtTA-producing BHK cell line. When the cell lines were cultured in the presence of tet (tetracycline) or tetracycline derivative doxycycline, the recombinant VSV and wild type VSV were replicated, whereas in the absence of tet or tetracycline derivative doxycycline, the recombinant VSV was not replicated. Viral supernatants were harvested, diluted, and monitored by plaque assay for the presence of infectious VSV. Plaques of VSV containing an additional sequence encoding the EGFP protein allowed rapid detection of infection. Our results suggest wide applications of other surrogate viruses based on VSV. The availability of stable packaging cell lines represents a step toward the use of a VSV vector delivery system that can allow scale-up production of vector-stocks for gene therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16025245     DOI: 10.1007/s11262-005-1795-9

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.198


  32 in total

1.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.

Authors:  T R Fuerst; E G Niles; F W Studier; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

2.  Cell-mediated immunity to vesicular stomatitis virus infections in mice.

Authors:  R M Zinkernagel; B Adler; J J Holland
Journal:  Exp Cell Biol       Date:  1978

3.  Amplification, expression, and packaging of foreign gene by influenza virus.

Authors:  W Luytjes; M Krystal; M Enami; J D Parvin; P Palese
Journal:  Cell       Date:  1989-12-22       Impact factor: 41.582

4.  Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.

Authors:  A Roberts; E Kretzschmar; A S Perkins; J Forman; R Price; L Buonocore; Y Kawaoka; J K Rose
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3.

Authors:  K Dimock; P L Collins
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

6.  Cloned poliovirus complementary DNA is infectious in mammalian cells.

Authors:  V R Racaniello; D Baltimore
Journal:  Science       Date:  1981-11-20       Impact factor: 47.728

Review 7.  The evolution of RNA viruses: A population genetics view.

Authors:  A Moya; S F Elena; A Bracho; R Miralles; E Barrio
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

8.  Molecular cloning of natural paramyxovirus copy-back defective interfering RNAs and their expression from DNA.

Authors:  P Calain; J Curran; D Kolakofsky; L Roux
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

9.  Influenza B viruses with site-specific mutations introduced into the HA gene.

Authors:  W S Barclay; P Palese
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Infectious defective interfering particles of VSV from transcripts of a cDNA clone.

Authors:  A K Pattnaik; L A Ball; A W LeGrone; G W Wertz
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.